3rd Epigenetics in Drug Discovery conference
08 May 2013 - 10 May 2013 - Boston, MA, USA
GTC’s 3rd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel epigenetic mechanisms, therapeutics, developments, biomarkers and diagnostics. Venture Capitalists will also join the conference to discuss investment opportunities and what they look for in the epigenetics space.
Some key discussions around epigenetics drug discovery at the conference include: 1) The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc. 2) Novel mechanisms, biomarkers, technologies and diagnostics for epigenetics drug discovery 3) Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Astex, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc.
Conference sessions are:
Role of Epigenetics in Human Diseases
Drug Discovery in Epigenetics
Preclinical and Clinical Development
Epigenetic Biomarkers and Diagnostics
Panel Discussion: Investment Opportunities in the Epigenetic Space